NASDAQ: SEPN · Life Sciences · 6 alerts · CIK 1984086
Share price
$41.67Close, Nov 16
Market cap
$1.98B
Shares outstanding
47.55MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Septerna, Inc. filings on SEC EDGAR ↗
Jeffrey Finer, CEO, sold 18,500 shares of Septerna, Inc. at $42.09 to $46.16 a share (average $43.62) in 5 transactions, worth $807K in total on Nov 12, 2026. Shares held after the trade: 833,909 (-0.2%).
Septerna Director Alan Ezekowitz Sells $3.93M of Stock
Alan Ezekowitz, Director, sold 81,820 shares of Septerna, Inc. at $46.01 to $51.90 a share (average $48.09) in 7 transactions, worth $3.93M in total on Nov 11, 2026. Shares held after the trade: 35,600 (-2.9%).
Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery using its Native Complex Platform. As of November 4, 2026, the company had 47,549,223 shares of common stock outstanding and is classified as an emerging growth company and non-accelerated filer.
Septerna reported third quarter 2026 financial results and provided a business update, highlighting a cash position of $565.2 million which is expected to fund operations into mid-2029. The company expects Phase 1 clinical data for its PTH1R agonist SEP-479 in Q1 2027 and plans to initiate a Phase 1 trial for its newly selected Graves’ disease candidate, SEP-204, in the same period.
Term
Q3 2026
“We are building momentum across our portfolio, with an upcoming important clinical milestone for SEP-479, our oral PTH1R agonist for hypoparathyroidism, and the selection of SEP-204 as our oral TSHR NAM development candidate for Graves’ disease and thyroid eye disease.”
Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder
“With Phase 1 data for SEP-479 and the initiation a Phase 1 trial of SEP-204 expected in the first quarter of 2027, we are moving closer to realizing our ambition to translate our GPCR expertise into differentiated oral medicines for patients with significant unmet needs.”
Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder
Septerna announced the selection of SEP-204 as a development candidate for Graves’ disease and thyroid eye disease, supported by preclinical data presented at the 2026 American Thyroid Association Annual Meeting. The company also filed an updated corporate presentation for use in meetings with investors and analysts.
Septerna President and COO Elizabeth Bhatt Sells $150K of Stock
Elizabeth Bhatt, President and COO, sold 4,000 shares of Septerna, Inc. at $36.87 to $37.61 a share (average $37.41) in 2 transactions, worth $150K in total on Oct 15, 2026. Shares held after the trade: 174,209 (-1.6%).